TBC1D13: A Drug Target / Disease Biomarker (G54662)

Target Name: TBC1D13

NCBI ID: G54662

TBC1D13: A Drug Target / Disease Biomarker

TBC1D13 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the TBC1 family of proteins, which are known for their role in regulating gene expression and cell signaling. TBC1D13 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TBC1 family of proteins was identified through a combination of genetic and biochemical studies. The protein encoded by the TBC1D13 gene is composed of 1,942 amino acids and has a calculated molecular mass of 21.4 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in several signaling pathways.

One of the most significant functions of TBC1D13 is its role in cell signaling. The protein is involved in the regulation of several intracellular signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. TBC1D13 has been shown to play a role in the regulation of stem cell proliferation and differentiation, and is also involved in the regulation of tissue repair and regeneration.

In addition to its role in cell signaling, TBC1D13 is also involved in the regulation of gene expression. The protein has been shown to interact with several transcription factors, including NF-kappa-B, AP-1, and STAT3. It is also known to play a role in the regulation of microRNA (miRNA) expression, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

The potential drug target status of TBC1D13 is due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TBC1D13 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. The protein has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its involvement in cancer and neurodegenerative diseases, TBC1D13 is also involved in the regulation of autoimmune disorders. The protein has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

The potential drug target status of TBC1D13 is due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein has been shown to play a critical role in the regulation of cell signaling and gene expression, and is therefore an attractive target for drug development. Further research is needed to fully understand the function of TBC1D13 and its potential as a drug target.

Protein Name: TBC1 Domain Family Member 13

Functions: Acts as a GTPase-activating protein for RAB35. Together with RAB35 may be involved in regulation of insulin-induced glucose transporter SLC2A4/GLUT4 translocation to the plasma membrane in adipocytes

More Common Targets